https://www.switzerlandhealthmonitor.com/article/906173515-the-medical-affairs-professional-society-maps-announces-presenters-for-their-2026-emea-annual-meeting-in-zurich Switzerland Health Monitor en PressRelease 2026-04-20T14:00:00+00:00 The Medical Affairs Professional Society (MAPS) Announces Presenters for their 2026 EMEA Annual Meeting in Zurich https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24834739-new-zurich-logo-1000x346.png https://www.switzerlandhealthmonitor.com/article/906937311-newcelx-updates-corporate-presentation-to-highlight-type-1-diabetes-flagship-program-following-strategic-collaboration-with-eledon-pharmaceuticals Switzerland Health Monitor en PressRelease 2026-04-20T11:37:00+00:00 NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference https://ml.globenewswire.com/media/ac801d4e-6ea5-4452-87c2-aa6a05bec73c/small/logo-positive-2x-jpg.jpg https://www.switzerlandhealthmonitor.com/article/906909326-oculis-announces-completion-of-last-patient-visit-in-phase-3-diamond-program-with-ocs-01-eye-drops-for-the-treatment-of-diabetic-macular-edema Switzerland Health Monitor en PressRelease 2026-04-20T08:00:00+00:00 Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema https://ml-eu.globenewswire.com/media/f6fa6e90-83a4-4baa-a3b6-5483017d26b9/small/oculis-logo-gradient-jpg-resized-jpg.jpg